INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10625761		
Filing Date			2003-07-23		
	First Named Inventor	Thom	nas A. Bachman, II		
	Art Unit		2817		
	Examiner Name	Micha	nel B. Shingleton		
	Attorney Docket Number		ANCO/67US		

	U.S.PATENTS				Remove		
Examiner Initial*			Kind Code <sup>1</sup> Issue Date		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5699383		1997-12-16 Ichiyoshi			
	2	5963090		1999-10-05	Fukuchi		
	3	5970053		1999-10-19	Schick et al.		
	4	6047177		2000-04-04	Wickman		
	5	6078216		2000-06-20	Proctor, Jr.		
	6	6175747	B1	2001-01-16 Tanishma et al. 2002-06-04 McLaren			
	7	6400223	B1				
	8	6600792	B2	2003-07-29	Antonio et al.		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number Filing Date		10625761		
		2003-07-23		
First Named Inventor Thom		as A. Bachman, II		
Art Unit		2817		
Examiner Name Micha		nel B. Shingleton		
Attack Desirat North	nr.	ANCOR7US		

	9	6714073	B2	2004-03	1-30	Suto et al.					
If you wish	f you wish to add additional U.S. Patent citation information please click the Add button.  Add										
			U.S.P	ATENT	APPLI	CATION PUBL	ICATIONS		Remove		
			Name of Patentee or Applicant Releva			Columns,Lines where ant Passages or Relevant s Appear					
	1										
If you wisi	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Add	buttor	Add .		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	r Cite Foreign Document Country Kind Publication Name of Patentee or Applicant of cited Number³ Code² j Code⁴ Date Pocument			where Rel	or Relevant	тя					
	1										
If you wish	h to ac	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc), d					Τs
	,										
If you wish	h to a	d additional non-pater	t literatu	re docur	ment cit	ation informati	on please click the	Add b	utton Ac	ld	
	EXAMINER SIGNATURE										
Examiner	Signa	ture					Date Conside	red	•		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

	Application Number		10625761	
	Filing Date		2003-07-23	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Thorn		nas A. Bachman, II	
	Art Unit		2817	
	Examiner Name Micha		hael B. Shingleton	
	Attorney Docket Numb	er	ANCO/67US	

See find. Codes of USPTO Planto Tocuments at view, USPTO, DOV or MPEP 901.04. \* Enter office that its such the document, by the two-later code, VIPO Standard ST3.3. \*\* Frequence painted consenset, the inclusion on the year of the region of the Engeren result procedure the sensel number of the painted consumer. \*\*
\*\*India of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*\*
\*\*Applicant is to place a check mark here if Engels interguage streamlession a statistical.\*\*

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10625761	
Filing Date		2003-07-23	
First Named Inventor Thorn		as A. Bachman, II	
Art Unit		2817	
Examiner Name Micha		el B. Shingleton	
Attorney Docket Number		ANCO/67US	

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

ioni oi die signatale.						
Signature	/Scott A. Striebruner/	Date (YYYY-MM-DD)	2006-11-13			
Name/Print	Scott A Stinehniner	Registration Number	38323			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DING YESPTO SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.